INM
InMed Pharmaceuticals Inc. · NASDAQ
- Market cap
- $8.5M
InMed Pharmaceuticals Inc. (INM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for INM, including 9 SEC filings, 3 insider trades and 1 M&A update. The most recent was published Nov 10, 2026.
Financial highlights
Full financials- Net income, TTM
- -$13.16M
- Cash
- $1.09M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39+71%
2026-05-242026-11-15
Mix2490d
- SEC Filings16(67%)
- Insider7(29%)
- M&A1(4%)
Activity · 52 weeks7746 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $34,572 worth of shares (2,640 units at $13.10) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- PRInMed Pharmaceuticals Completes Closing of Merger with Mentari TherapeuticsShares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Mentari Therapeutics, Inc.) (NASDAQ:INM) ("Mentari" or the "Company") today announced the completion of the previously disclosed merger between the Company and the privately held Mentari Therapeutics, Inc. ("pre-merger Mentari"). The combined company will continue to operate under the name Mentari Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market at market open on Monday, November 9, 2026, under the name "Mentari Therapeutics, Inc.," the ticker symbol "MTRI
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 10-Q filed by InMed Pharmaceuticals Inc.10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECSEC Form 424B3 filed by InMed Pharmaceuticals Inc.424B3 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $5 worth of shares (4 units at $1.32) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $1,435 worth of shares (1,087 units at $1.32) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $11,418 worth of shares (8,585 units at $1.33) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $4,051 worth of shares (3,046 units at $1.33) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $35,230 worth of shares (26,489 units at $1.33) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECSEC Form EFFECT filed by InMed Pharmaceuticals Inc.EFFECT - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 424B3 filed by InMed Pharmaceuticals Inc.424B3 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECAmendment: SEC Form S-4/A filed by InMed Pharmaceuticals Inc.S-4/A - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $118,076 worth of shares (91,101 units at $1.30) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECAmendment: SEC Form S-4/A filed by InMed Pharmaceuticals Inc.S-4/A - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECSEC Form 10-K filed by InMed Pharmaceuticals Inc.10-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
INM FAQ
9 questionsWhat does InMed Pharmaceuticals Inc. do?
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the...What is the latest news on INM?
In the last 30 days Quantisnow tracked 13 wire items for INM: 9 SEC filings, 3 insider trades and 1 M&A update. The most recent was published on November 10, 2026.Is INM profitable?
No. InMed Pharmaceuticals Inc. reported a net loss of $13.16M for the twelve months ended Sep 30, 2026.How much cash and debt does INM have?
InMed Pharmaceuticals Inc. reported $1.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does INM stock trade?
InMed Pharmaceuticals Inc. (INM) is listed on NASDAQ.What sector and industry is INM in?
InMed Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INM?
InMed Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $6.00 price target on 2021-11-29. Recent price targets cluster around $6.00.What companies are similar to INM?
Notable peers in the same industry include CRBP (Corbus Pharmaceuticals Holdings Inc.), JAZZ (Jazz Pharmaceuticals plc), TLRY (Tilray Brands Inc.). Compare INM side-by-side with any of them on Quantisnow.How can I track INM on Quantisnow?
Quantisnow aggregates InMed Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INM to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change